1,536 results on '"Michael, Nelson L"'
Search Results
102. Designing the epitope flanking regions for optimal generation of CTL epitopes
103. Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection
104. Supplement to: A recombinant vesicular stomatitis virus Ebola vaccine.
105. Transmission dynamics among participants initiating antiretroviral therapy upon diagnosis of early acute HIV-1 infection in Thailand
106. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals
107. Vaccine protection against Zika virus from Brazil
108. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model
109. Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand
110. Natural Killer Cell-Mediated Innate Sieve Effect on HIV-1: The Impact of KIR/HLA Polymorphism on HIV-1 Subtype-Specific Acquisition in East Africa
111. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
112. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E
113. Cooling Off the Host Immune Response to Acute Simian Immunodeficiency Virus Infection—Is Less More?
114. HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019
115. Prospects for a Zika Virus Vaccine
116. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
117. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
118. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
119. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144
120. HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019
121. HIV-1 infections with multiple founders associate with the development of neutralization breadth
122. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
123. Clinical signs and symptoms associated with acute HIV infection from an intensely monitored cohort on 2 continents
124. Class I HLA-A 7401 Is Associated with Protection from HIV-1 Acquisition and Disease Progression in Mbeya, Tanzania
125. Host Determinants of HIV-1 Control in African Americans
126. A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172)
127. Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression
128. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
129. Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant
130. Cross-Cutting Lessons Learned During the COVID-19 Pandemic—the Walter Reed Army Institute of Research Experience
131. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
132. Simplified steps to heterologous prime-boost HIV vaccine development?
133. FCGR2C polymorphisms associate with hiv-1 vaccine protection in rv144 trial
134. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
135. HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial
136. Costs and Consequences: Hepatitis C Seroprevalence in the Military and Its Impact on Potential Screening Strategies
137. Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions
138. Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants.
139. Prospective Analyses of HIV-1-Specific Proliferative Responses, Recall Antigen Proliferative Responses, and Clinical Outcomes in an HIV-1-Seropositive Cohort
140. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
141. Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
142. Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment
143. Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
144. Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
145. Author response: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1
146. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth
147. SARS-CoV-2 Variants in Patients with Immunosuppression
148. CCR2-641 Polymorphism, Syncytium-Inducing Human Immunodeficiency Virus Strains, and Disease Progression
149. Shorter Survival of SDF1-3' A/3' Homozygotes Linked to CD4⁺ T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection
150. RAPID ESTABLISHMENT OF THE VIRAL RESERVOIR PRIOR TO SYSTEMIC VIREMIA FOLLOWING MUCOSAL SIV INFECTION OF RHESUS MONKEYS: O1.07
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.